Compare KLTR & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | OBIO |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.0M | 253.9M |
| IPO Year | 2021 | 2020 |
| Metric | KLTR | OBIO |
|---|---|---|
| Price | $1.60 | $5.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $3.00 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 1.1M | 294.8K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,854,000.00 | $33,482,000.00 |
| Revenue This Year | $2.96 | N/A |
| Revenue Next Year | $4.96 | $12.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.20 | ★ 1169.22 |
| 52 Week Low | $1.06 | $2.20 |
| 52 Week High | $2.05 | $5.78 |
| Indicator | KLTR | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 64.97 |
| Support Level | $1.56 | $3.72 |
| Resistance Level | $1.68 | $5.42 |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 38.02 | 63.92 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.